Ben is a recovering investment banker turned entrepreneur focused on addressing the biggest problems in human health, in terms of individual health and resilience as well as global health. This ambition led Ben to a focus on mitochondrial biology as the central mediator of adaptive stress response (allostasis), and on the emerging paradigm of the mitochondrial etiology of complex diseases of aging to present both non-pharmacological and pharmacological interventions for health optimization and treatment of disease. Ben joined Pano Therapeutics, Inc. as Co-founder & CEO in 2019.